Exploring Features of Viking and Summit for Investors

Evaluating Two Strong Performers

Shares of Viking Therapeutics and Summit Therapeutics have significantly outperformed the market this year. Both companies have witnessed their stock prices surge due to favorable news, including promising developments in Viking's oral weight-loss drug and optimistic results for Summit's cancer therapy.

While significant gains are impressive, analysts remain optimistic about the future. Oppenheimer analyst Jay Olson Ulz projects that Viking Therapeutics could see its stock rise to $138 per share, indicating a potential gain of roughly 112%. Similarly, at Citi, analyst Yigal Nochomovitz predicts that Summit Therapeutics shares could climb around 120%, reaching $42 per share in the coming months.

Viking Therapeutics: A Potential Leader in Weight Loss

The market for weight management drugs is booming, currently exceeding $45 billion annually, with forecasts suggesting it could surpass $150 billion in the next few years. A noteworthy candidate from Viking Therapeutics is VK2735, a promising treatment expected to capture a substantial share of this lucrative market. An injectable version of VK2735 has recently entered a phase 3 trial.

In earlier phase 2 trials, VK2735 demonstrated an impressive 15% weight reduction in patients after 13 weeks while maintaining a strong safety profile. Investors are especially enthusiastic about the oral tablet version of VK2735, which led to a 5.3% reduction in weight after just 28 days of dosing in a phase 1 study.

An anticipated phase 2 study for the oral version is set to begin by year's end. With its compelling safety data, Olson believes it has the potential to be the first over-the-counter weight management drug targeting both GLP-1 and GIP receptors.

Summit Therapeutics: Pioneering Cancer Treatment

As the market for cancer therapies continues to grow, specifically those acting on the PD-1 pathway, Summit Therapeutics is well-positioned to make its mark with a new treatment, ivonescimab. This bispecific antibody targets both PD-1 and vascular endothelial growth factor (VEGF), an exciting twist in cancer therapy.

Remarkably positive outcomes in trials have propelled Summit's stock price up by more than 600% in 2024. The efficacy of ivonescimab was highlighted in the Harmoni-2 trial, where it outperformed Keytruda, currently the top-selling PD-1 drug with sales reaching $25 billion last year. The data indicated that lung cancer patients treated with ivonescimab were 49% less likely to experience disease progression compared to those receiving Keytruda alone.

Although ivonescimab has already gained marketing approval in China, it awaits pivotal studies involving U.S. patients. Summit's full range of international phase 3 trials is actively recruiting participants, aiming for further data by early 2025.

Investment Considerations: Viking and Summit

Summit has entered an agreement for the rights to ivonescimab, which includes paying Akeso a percentage of sales outside China. The escalating market valuation, currently $14 billion, may suggest a bubble, prompting investors to wait for further trial success before considering an investment in Summit shares.

On the other hand, Viking Therapeutics' modest market cap of $7.2 billion could soar if VK2735 continues to achieve favorable results in trials. For investors open to risk, incorporating Viking shares into a diversified portfolio could be a wise strategy.

Should You Invest in Viking Therapeutics?

Before making any decisions regarding an investment in Viking Therapeutics, keep a few factors in mind. First, while the potential for high returns exists, it is always prudent to assess the associated risks with any investment strategy.

Furthermore, the market dynamics involve fluctuations and what works well today may change tomorrow. Thoroughly evaluating the financial landscape and the promising developments with Viking and Summit will provide a clearer perspective on potential investment opportunities, especially with the ongoing developments in the pharmaceutical sector.

Frequently Asked Questions

What are the key products of Viking Therapeutics?

Viking Therapeutics is advancing VK2735, a weight-loss treatment currently in various clinical trial phases, showing promising results in reducing weight.

How has Summit Therapeutics performed in the market?

Summit Therapeutics has significantly increased its stock price due to the success of ivonescimab, a cancer therapy that has shown superior efficacy compared to Keytruda.

What is the market forecast for anti-obesity drugs?

The demand for anti-obesity medications is projected to exceed $150 billion annually over the next few years, indicating strong market growth potential.

What are the risks associated with investing in biomedical stocks?

Biomedical stocks can be highly volatile, with success depending on trial results and regulatory approvals, making thorough research essential before investing.

What should investors consider about Viking Therapeutics?

Investors should weigh the potential high returns against the risks associated with clinical trials and the fast-evolving pharmaceutical market landscape.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.